SCLC is an aggressive disease subtype and accounts for 15% of patients with lung cancer, being less common than non-small-cell lung cancer (NCSLC). ES-SCLC has a median survival of around 9-12 months.

The Sen lab at the Icahn School of Medicine at Mount Sinai investigates the biology of recalcitrant subtypes of lung cancer ... landscape for extensive-stage SCLC." The study's findings are ...

PE: The ADRIATIC trial demonstrated significant survival benefits for LS-SCLC patients. How do you envision this approval changing the standard treatment paradigm for these patients? Ghattas: LS-SCLC ...

Study defines small-cell lung cancer subtypes and distinct therapeutic vulnerabilities for each type University of Texas M. D. Anderson Cancer Center Journal Cancer Cell DOI 10.1016/j.ccell.2020. ...